EU re-inspection delay
EU audit (Hungary) expected in May-June 2026; any delay could postpone regulated market revenue.
LINCOLNPHARMACEUTICALS / Q3-FY26 / risks
Keep the risk register visible.
Lincoln Pharmaceuticals · Material risks, their source context, and severity in the latest available quarter.
Research layer active
ConCallIQ research layer
Signal, with the source still visible.
Use the controls below to narrow the view, then follow the evidence into the next layer of context.
Risk intelligence
Material risks this quarter
medium
High other income dependence
Other income (forex gains, investment returns) is volatile and contributed ~50% of PBT in 9M; sustainability uncertain.
Inorganic growth execution risk
Management is holding cash for acquisitions; if no suitable target found, cash drag may persist.
Geopolitical risk in Africa
Africa contributes 40% of exports; currency fluctuations and payment delays are inherent risks.